- Research article
- Open Access
A novel splice variant of folate receptor 4 predominantly expressed in regulatory T cells
- Yi Tian†1,
- Guoqiang Wu†2,
- Jun-Chao Xing†2,
- Jun Tang3,
- Yi Zhang1,
- Ze-Min Huang1,
- Zheng-Cai Jia1,
- Ren Zhao1,
- Zhi-Qiang Tian1,
- Shu-Feng Wang1,
- Xiao-Ling Chen1,
- Li Wang1,
- Yu-Zhang Wu1Email author and
- Bing Ni1Email author
© Tian et al.; licensee BioMed Central Ltd. 2012
- Received: 23 March 2012
- Accepted: 13 June 2012
- Published: 13 June 2012
Regulatory T cells (Tregs) are required for proper maintenance of immunological self-tolerance and immune homeostasis. Folate receptor 4 (FR4) is expressed at high levels in transforming growth factor-beta (TGF-β)-induced Tregs and natural Tregs. Moreover, antibody-mediated targeting of FR4 is sufficient to mediate Treg depletion.
In this study, we describe a novel FR4 transcript variant, FR4D3, in which exon 3 is deleted. The mRNA of FR4D3 encodes a FR4 variant truncated by 189 bp. FR4D3 was found to be predominantly expressed in CD4+CD25+ Treg cells. Overexpression of FR4D3 in CD4+CD25+ Treg cells in vitro stimulated proliferation, which may modulate the ability of these cells to bind and incorporate folic acid.
Our results suggested that high levels of FR4D3 may be critical to support the substantial proliferative capacity of Treg cells.
- Folate receptor 4
- Regulatory T cells
The folate receptor (FR), also known as the folic acid (FA) binding protein, is responsible for binding of 5-methyltetrahydrofolate (5-MeTHF) with high affinities (~100 pM Kd), thereby playing an important role in the uptake of serum folates by cells expressing this receptor[1, 2]. Four isoforms of the human FR, FR-α, -β, -γ and –δ, have been identified and characterized. FR-α is predominantly expressed on epithelial cells[3, 4]. FR-β is expressed only on activated macrophages and the surfaces of malignant cells of hematopoietic origin. FR-γ was identified as a secretory protein from hematopoietic tissues, and demonstrated to have a much lower affinity for FA than FR-α[6, 7]. FR-δ has proven difficult to detect in human tissues, suggesting a highly restricted spatial/temporal expression pattern, presence of a pseudogene, or predominance of an alternatively spliced variant. Recent data, however, has indicated that FR-δ may be expressed on regulatory T cells (Tregs).
Analysis of amino acid sequences in the mouse led to the identification of homologues of human FR-α and FR-β, known as folic acid-binding protein 1 and 2 (Folbp1/FR1 and Folbp2/FR2). Utilizing a ‘genome database mining’ strategy, Spiegelstein et al. identified a third murine FR, Folbp3 (also called FR4), which is highly homologous to human FR-δ[8, 11]. In addition to regulating FA uptake, FR4 has been hypothesized to play a potential role in immune responses based upon its expression profile, which includes spleen- and thymus-related lymphoid tissues and lymphocytes. Indeed, FR4 has been demonstrated to be exclusively expressed in splenic lymphocytes, especially in the T lymphocytes, and in mature thymocytes; however, few studies have reported on the characterization of FR4[8, 11].
Tregs are required for proper maintenance of immunological self-tolerance and immune homeostasis. Studies to identify molecular markers of Tregs determined that FR4 is expressed at particularly high amounts in natural (n)Tregs and plays an important role in the maintenance of the Treg phenotype. In our previous study, we identified a FR4 cDNA splice variant (FR4v) with intron 3 (108 bp) retained from the FR4 gene and confirmed protein expression of this variant. Here, we report the identification of another FR4 transcript variant, named FR4D3, with the full-length exon 3 (189 bp) deleted. The FR4D3-encoded protein was confirmed to be expressed on CD4+CD25+ Tregs by Western blotting and fluorescence-activated cell sorting (FACS) assays. Finally, the role of the FR4D3 variant was investigated by overexpression in Treg cells in vitro.
Isolation of RNA, amplification and cloning of FR4D3
Six to eight-week-old female BALB/c mice were purchased from the Animal Center at the Chinese Academy of Medical Science(CAMS) branch in Beijing, China. All animals were maintained in pathogen-free conditions. All of the animal studies were approved by the Institutional Animal Care and Use Committee of the Third Military Medical University.
Total RNA was extracted from BALB/c mouse splenocytes using the TRIzol® reagent (Invitrogen, USA) according to the manufacturer's instructions. Approximately 1 μg of total RNA was reverse transcribed to cDNA using the High Fidelity PrimeScript™ reverse transcription-polymerase chain reaction (RT-PCR) kit (TaKaRa, Japan). The cDNA was then used as template to PCR amplify the FR4 coding DNA sequence (CDS) with the following primers corresponding to the ends of exons 2 and 5 of the mouse FR4 gene, respectively: mFR4-F, 5'-ATGGCACAGTGGTGGCAGAT-3'; mFR4-R, 5'-TCAGG GATGGAACAACAGGC-3'. The PCR reaction was carried out under the following thermal cycling conditions: 30 cycles of 98°C for 10 s and 68°;C for 40 s. The PCR amplicons were then subcloned into the pMD19-T vector (TaKaRa), and the clones were fully sequenced at Shanghai Sangon Biological Engineering Technology & Services Co., Ltd (China). The mRNA expression of FR4, FR4v and FR4D3 genes in splenocytes, CD4+ T cells, and CD4+CD25+ T cells were detected using RT-PCR assays with the following primers: 5'-GGGACAAACTGCTCAGCGTCT-3' (forward) and 5'-AGACACCGCCCACTGTTCCT-3' (reverse).
To construct FR4- or FR4D3- expressing recombinant plasmids, the FR4 or FR4D3 coding sequence was PCR-amplified from BALB/c mouse splenocytes RNA and cloned directly into the pCI-neo vector (Promega, USA). The following primers were used: Forward primer: 5'-CCGCTCGAGGCCACCATGGCACAGTGGTGGCAGAT-3'; Reverse primer: 5'-CGTGGGTGCTCTAGATCAGGGATGGAACAACAGGC-3'.
Approximately 1 × 108 splenocytes were stained with anti-CD4-FITC, anti-CD25-PE and anti-CD8- PerCP-Cy5.5 antibodies (all from eBioscience, USA). The stained cells were separated by FACS into batches of CD4+CD25+ T cells, CD4+CD25- T cells, and CD8+ T cells with a FACS-Aria high-speed cell sorter (BD Biosciences, USA). The isolated CD4+CD25+ T cells were stained with intracellular anti-FOXP3-APC antibody (eBioscience, USA) and then detected by the FACS-Aria high-speed cell sorter.
Western blotting analysis
Isolated splenocytes and T cell subsets CD4+CD25–, CD4+CD25+, or CD8+ were lysed with the T-PER® Tissue Protein Extraction Reagent (Pierce, USA) at room temperature. After 5 min of lysis, the cell debris was removed via centrifugation at 12,000 rpm for 5 min at 4°;C and the lysates were treated with N-glycosidase before blotting. The protein-containing supernatant was mixed with 4 × nonreducing lithium dodecyl sulfate (LDS) sample buffer (Invitrogen) and heated for 10 min at 70°;C. The protein samples (10–50 μg) were resolved by electrophoresis through NuPAGE® Novex 10% Bis-Tris mini-gels (Invitrogen) and transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore, Germany). After blocking of non-specific sites, the membranes were incubated with primary antibody (1:1,000 rat anti-mouse FR4; Abcam, United Kingdom) at 4°;C overnight, followed by incubation with secondary antibody (1:10,000 goat anti-rat IgG; Abcam) for 1 h. Immunoreactive bands were observed using the enhanced chemiluminescence (ECL) detection reagents (Amersham Biosciences, United Kingdom), according to the manufacturer’s instructions. β-actin was detected as an internal control (primary antibody: rabbit anti-mouse β-actin, secondary antibody: goat anti-rabbit IgG; both from Abcam).
The pCI-neo-FR4 or pCI-neo-FR4D3 vector (0.5 μg) was added to 2 × 104 FACS-sorted CD4+CD25+ Tregs resuspended in 100 μL of mouse T cell Nucleofector solution and electroporated using the 96-DN-100 program on the Nucleofector instrument (Lonza, Germany). After 24 h of culture in serum-free conditions, the expressions of FR4 and FR4D3 proteins in the respective transfected cells were analyzed with Western blotting assay using anti-mouse FR4 (Abcam) as the primary antibody. The immunoreactive bands were scanned and densitometric analysis was performed by Bio-Rad Quantity One software.
The FACS-sorted CD4+CD25+ Tregs were stimulated with various concentrations of FA (0, 2, 4, 6, 8, 10 ng/mL; Sigma-Aldrich, USA) in the presence of interleukin (IL)-2 (300 U/mL; R&D Systems, USA), anti-CD3 (5 μg/mL; BD Biosciences)/anti-CD28 (2 μg/mL; BD Biosciences) (pre-coated and soluble, respectively). Cultures were incubated for three days and labeled with 0.5 μCi (0.0185 MBq) [3H]thymidine ([3H]TdR; Hartmann Analytics, Germany) during the last 18 hours of incubation. [3H]TdR incorporation was measured by a liquid scintillation counter (Top Count; Perkin Elmer, Germany). All assays were performed in triplicate.
The CD4+CD25+ Tregs transfected with pCI-neo-FR4 or pCI-neo-FR4D3 plasmids were seeded in 96-well U-bottom plates pre-coated with anti-CD3(5 μg/mL) and co-stimulated for three days with soluble anti-CD28 (2 μg/mL), with or without IL-2 (300 U/mL) or FA (4, ng/mL). During the last 18 hours of culture, cells were labeled with 0.5 μCi (0.0185 MBq) [3H]thymidine. [3H]thymidine incorporation was measured by a liquid scintillation counter. All assays were performed in triplicate.
Relative comparisons of FR4 and FR4D3 proteins’ intensity abundance between the transfected cells and untransfected cells detected by Western blot assay and the differences in proliferation of sorted CD4+CD25+ Tregs were analyzed by means of the 2-tailed Student’s t-test. P- values less than 0.05 were considered significant.
Identification of a novel FR4 isoform
Since the 189 bp-length exon 3 is composed of exactly 63 triplet codes of the FR4 mRNA, its elimination will not change the correct translation of FR4D3 mRNA. Therefore, Western blotting assay was used to determine whether the FR4D3 protein was expressed in mouse spleen cells. As shown in Figure1E, the anti-FR4 antibody detected both the full-length FR4 and the truncated FR4D 3 variant in mouse splenocytes, whose predicted molecular masses were approximately 28 kDa and 21 kDa, respectively. The sequence and theoretical translation of this novel cDNA were submitted to GenBank and can be found under accession numbers EU326439.1 and ABY56299.1, respectively.
Predominant expression of FR4D3 in CD4+CD25+ regulatory T cells
Effect of overexpression of FR4D3 on proliferation of CD4+CD25+ T cells
In this study, we have identified a novel alternative splicing variant of the FR4 gene, named FR4D3, which lacks the entire exon 3 of the FR4 gene. FR4D3 proteins were found to be expressed in CD4+CD25+ Tregs at a higher level than in CD4+CD25- or CD8+ T cells. Furthermore, overexpression of FR4D3 in FACS-sorted CD4+CD25+ Tregs was found to enhance proliferative capacity of these cells in vitro.
Recent studies have demonstrated that nearly every multi-exon gene, including “constitutively” spliced genes, produces alternative mRNA isoforms. Although many of these isoforms have important functional roles, it is clear that some of these mRNAs are produced by errors that occur during the splicing process. In fact, different RNA quality controls have evolved to recognize and degrade such errors. For those mRNAs that escape detection and destruction, expression may be at such low levels that the new mRNA isoforms may be tolerated by the cell, eventually representing an evolutionary precursor[20, 21].
Previous studies have suggested that FR4 is exclusively expressed by splenic lymphocytes, especially the T lymphocytes, and mature thymocytes. Subsequent study identified particularly high expression in the nTregs T cell subpopulation. In our current study, we found that FR4D3 was expressed in CD4+CD25+ Tregs at a higher level than in either CD4+CD25- or CD8+ T cells, suggesting that the expression of FR4D3 was cell type-specific. Retroviral transduction of Foxp3, which can functionally and phenotypically convert normal T cells to natural Treg-like cells[22, 23], has revealed that the FR4 expression was proportional to that of Foxp3 in Foxp3-transduced CD25-CD4+ T cells, suggesting that Foxp3 can control, either directly or indirectly, the expression of FR4 in natural Treg cells. Further research is necessary to determine whether transduction with Foxp3 is also sufficient to mediate FR4D3 up-regulation.
As previously described for CD4+CD25+ Tregs, the anergic state of a pure CD4+CD25+ Treg subpopulation is abrogated after simultaneous stimulation of T cell receptors (TCRs) and CD28 in the presence of IL-2; neither IL-2 nor plate-bound anti-CD3 combined with soluble anti-CD28 could resolve the cells’ unresponsiveness[24, 25]. Furthermore, the capacity to efficiently bind and incorporate folic acid is linked to cellular proliferation, in both normal and tumorigenic conditions. In our current study, we found that overexpressing FR4D3 or FR4 in CD4+CD25+ Tregs could further enhance the proliferation induced by FA, IL-2, and anti-CD3/anti-CD28 (pre-coated and soluble, respectively) in vitro. These results suggested that high expression of FR4D3 could facilitate binding of FA and cellular uptake, which may be critical to support the substantial proliferative capacity of Tregs in vivo. Of course, the FR4D3 may have other yet unrecognized functions, which will require further investigation. We also found that the FA + IL-2+ anti-CD3/anti-CD28 induced proliferative capacity of CD4+CD25+ Tregs overexpressing FR4D3 was weaker than in CD4+CD25+ Tregs overexpressing FR4. These results suggested that the exon 3-related sequences contribute to optimal FA binding and/or cellular uptake mediated by FR4.
In conclusion, we have identified a novel exon 3-deleted FR4 transcript variant, which encodes a 189 bp truncated protein that is predominantly expressed in CD4+CD25+ Treg cells. The high expression of FR4D3 in CD4+CD25+ Tregs may modulate the ability of these cells to bind and incorporate folic acid, possibly in normal or pathogenic conditions that would benefit from enhanced proliferation of these cells.
This work was supported by grants from the General Program of National Natural Science Foundation of China (Nos. 31070798 and 30901337) and the Key Program of the National Natural Science Foundation of China (30930086).
- Shen F, Ross JF, Wang X, Ratnam M: Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry. 1994, 33 (5): 1209-1215. 10.1021/bi00171a021.PubMedView ArticleGoogle Scholar
- Antony AC: Folate receptors. Annu Rev Nutr. 1996, 16: 501-521. 10.1146/annurev.nu.16.070196.002441.PubMedView ArticleGoogle Scholar
- Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA: Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res. 1992, 52 (23): 6708-6711.PubMedGoogle Scholar
- Kamen BA, Smith AK: A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev. 2004, 56 (8): 1085-1097. 10.1016/j.addr.2004.01.002.PubMedView ArticleGoogle Scholar
- Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS: A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood. 2009, 113 (2): 438-446.PubMedView ArticleGoogle Scholar
- Shen F, Wu M, Ross JF, Miller D, Ratnam M: Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry. 1995, 34 (16): 5660-5665. 10.1021/bi00016a042.PubMedView ArticleGoogle Scholar
- Blom HJ: Folic acid, methylation and neural tube closure in humans. Birth Defects Res A Clin Mol Teratol. 2009, 85 (4): 295-302. 10.1002/bdra.20581.PubMedView ArticleGoogle Scholar
- Spiegelstein O, Eudy JD, Finnell RH: Identification of two putative novel folate receptor genes in humans and mouse. Gene. 2000, 258 (1–2): 117-125.PubMedView ArticleGoogle Scholar
- Low PS, Kularatne SA: Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009, 13 (3): 256-262. 10.1016/j.cbpa.2009.03.022.PubMedView ArticleGoogle Scholar
- Barber RC, Bennett GD, Greer KA, Finnell RH: Expression patterns of folate binding proteins one and two in the developing mouse embryo. Mol Genet Metab. 1999, 66 (1): 31-39. 10.1006/mgme.1998.2772.PubMedView ArticleGoogle Scholar
- Elnakat H, Ratnam M: Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004, 56 (8): 1067-1084. 10.1016/j.addr.2004.01.001.PubMedView ArticleGoogle Scholar
- Vignali DA, Collison LW, Workman CJ: How regulatory T cells work. Nat Rev Immunol. 2008, 8 (7): 523-532. 10.1038/nri2343.PubMedPubMed CentralView ArticleGoogle Scholar
- Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, Nomura T, Sakaguchi S: Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity. 2007, 27 (1): 145-159. 10.1016/j.immuni.2007.04.017.PubMedView ArticleGoogle Scholar
- Jia Z, Zhao R, Tian Y, Huang Z, Tian Z, Shen Z, Wang Q, Wang J, Fu X, Wu Y: A novel splice variant of FR4 predominantly expressed in CD4 + CD25+ regulatory T cells. Immunol Invest. 2009, 38 (8): 718-729. 10.3109/08820130903171003.PubMedView ArticleGoogle Scholar
- Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002, 3 (2): 135-142. 10.1038/ni759.PubMedView ArticleGoogle Scholar
- Sega EI, Low PS: Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev. 2008, 27 (4): 655-664. 10.1007/s10555-008-9155-6.PubMedView ArticleGoogle Scholar
- Fox-Walsh KL, Hertel KJ: Splice-site pairing is an intrinsically high fidelity process. Proc Natl Acad Sci USA. 2009, 106 (6): 1766-1771. 10.1073/pnas.0813128106.PubMedPubMed CentralView ArticleGoogle Scholar
- Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ: Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008, 40 (12): 1413-1415. 10.1038/ng.259.PubMedView ArticleGoogle Scholar
- Hsu SN, Hertel KJ: Spliceosomes walk the line: splicing errors and their impact on cellular function. RNA Biol. 2009, 6 (5): 526-530. 10.4161/rna.6.5.9860.PubMedPubMed CentralView ArticleGoogle Scholar
- Sestili P, Barbieri E, Martinelli C, Battistelli M, Guescini M, Vallorani L, Casadei L, D'Emilio A, Falcieri E, Piccoli G: Creatine supplementation prevents the inhibition of myogenic differentiation in oxidatively injured C2C12 murine myoblasts. Mol Nutr Food Res. 2009, 53 (9): 1187-1204. 10.1002/mnfr.200800504.PubMedView ArticleGoogle Scholar
- Annibalini G, Guescini M, Agostini D, Matteis RD, Sestili P, Tibollo P, Mantuano M, Martinelli C, Stocchi V: The expression analysis of mouse interleukin-6 splice variants argued against their biological relevance. BMB Rep. 2012, 45 (1): 32-37. 10.5483/BMBRep.2012.45.1.32.PubMedView ArticleGoogle Scholar
- Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY: A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005, 6 (11): 1142-1151. 10.1038/ni1263.PubMedView ArticleGoogle Scholar
- Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003, 299 (5609): 1057-1061. 10.1126/science.1079490.PubMedView ArticleGoogle Scholar
- Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M: Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood. 2004, 104 (3): 895-903. 10.1182/blood-2004-01-0086.PubMedView ArticleGoogle Scholar
- Fantini MC, Dominitzki S, Rizzo A, Neurath MF, Becker C: In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells. Nat Protoc. 2007, 2 (7): 1789-1794. 10.1038/nprot.2007.258.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.